Associations between good days per month and migraine-related disease impact in the real-world: a post hoc analysis from the REVIEW study of eptinezumab in chronic migraine

Fawad A. Khan, Steven P. Herzog, Ryan M. Smith, Dawn C. Buse, Seema Soni-Brahmbhatt, Susanne F. Awad, S. Wald Grossman, Divya Asher, Foram Patel, Charles Argoff

Open source

DOI
10.1186/s10194-025-02227-5
Published
2025-11-26
Container
The Journal of Headache and Pain
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s10194-025-02227-5,
  title = {Associations between good days per month and migraine-related disease impact in the real-world: a post hoc analysis from the REVIEW study of eptinezumab in chronic migraine},
  author = {Fawad A. Khan and Steven P. Herzog and Ryan M. Smith and Dawn C. Buse and Seema Soni-Brahmbhatt and Susanne F. Awad and S. Wald Grossman and Divya Asher and Foram Patel and Charles Argoff},
  year = {2025},
  journal = {The Journal of Headache and Pain},
  doi = {10.1186/s10194-025-02227-5},
  url = {https://doi.org/10.1186/s10194-025-02227-5}
}

RIS

TY  - JOUR
TI  - Associations between good days per month and migraine-related disease impact in the real-world: a post hoc analysis from the REVIEW study of eptinezumab in chronic migraine
AU  - Fawad A. Khan
AU  - Steven P. Herzog
AU  - Ryan M. Smith
AU  - Dawn C. Buse
AU  - Seema Soni-Brahmbhatt
AU  - Susanne F. Awad
AU  - S. Wald Grossman
AU  - Divya Asher
AU  - Foram Patel
AU  - Charles Argoff
PY  - 2025
JO  - The Journal of Headache and Pain
DO  - 10.1186/s10194-025-02227-5
UR  - https://doi.org/10.1186/s10194-025-02227-5
ER  - 

APA

Khan, F. A., Herzog, S. P., Smith, R. M., Buse, D. C., Soni-Brahmbhatt, S., Awad, S. F., Grossman, S. W., Asher, D., Patel, F., & Argoff, C. (2025). Associations between good days per month and migraine-related disease impact in the real-world: a post hoc analysis from the REVIEW study of eptinezumab in chronic migraine. The Journal of Headache and Pain. https://doi.org/10.1186/s10194-025-02227-5

Source records